Ipilimumab for advanced melanoma: Experience from the Spanish Expanded Access Program

Melanoma Research

Volumn 24, Issue 6, 2014, Pages 577-583

  Berrocal, Alfonso ^a   Arance, Ana ^c   Martin, Jose Antonio Lopez ^e   Soriano, Virtudes ^b   Muñoz, Eva ^d   Alonso, Lorenzo ^h   Espinosa, Enrique ^f   Criado, Pilar Lopez ^g   Valdivia, Javier ⁱ   Algarra, Salvador Martin ^j  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^b INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^g MD ANDERSON CANCER CENTER   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^j UNIVERSITY CLINIC OF NAVARRA   (Spain)

more..

Author keywords

Expanded access program; Ipilimumab; Melanoma; Questionnaire; Retrospective study

Indexed keywords

IPILIMUMAB; LACTATE DEHYDROGENASE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BRAIN METASTASIS; CANCER PATIENT; CANCER SURVIVAL; COMPASSIONATE USE; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; SURVIVAL FACTOR; SURVIVAL PREDICTION; TREATMENT DURATION; HEALTH CARE DELIVERY; MELANOMA; MIDDLE AGED; PATHOLOGY; QUESTIONNAIRE; SKIN NEOPLASMS; SPAIN; SURVIVAL ANALYSIS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COMPASSIONATE USE TRIALS; DISEASE PROGRESSION; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALE; MELANOMA; MIDDLE AGED; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SPAIN; SURVEYS AND QUESTIONNAIRES; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84916881425     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000108     Document Type: Article

References (28)

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Melanoma: Version 2 2013; Washington: National Comprehensive Cancer Network. Available at: http://www.nccn.org/professionals/physician-gls/pdf/melanoma.pdf. [Accessed 28 May 2013].
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2 Cancer incidence and mortality worldwide: IARC Cancer Base No. 10. 2010. Available at: http://globocan.iarc.fr [Accessed 28 May 2013].
3. Gasent Blesa JM, Grande Pulido E, Alberola Candel V, Provencio Pulla M. Melanoma: from darkness to promise. Am J Clin Oncol 2011; 34:179-187.
4. American Cancer Society. Melanoma skin cancer 2013; New York: American Cancer Society. Available at: http://www.cancer.org/acs/groups/cid/documents/webcontent/003120-pdf.pdf. [Accessed 28 May 2013].
5. Dummer R, Hauschild A, Guggenheim M, Jost L, Pentheroudakis G. ESMO Guidelines Working Group. Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl 5): v194-v197.
6. Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncology (Williston Park) 2009; 23:488-496.
7. Boyle GM. Therapy for metastatic melanoma: an overview and update. Expert Rev Anticancer Ther 2011; 11:725-737.
8. Lee B, Mukhi N, Liu D. Current management and novel agents for malignant melanoma. J Hematol Oncol 2012; 5:3.
9. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-2526.
10. Hanaizi Z, van Zwieten-Boot B, Calvo G, Lopez AS, van Dartel M, Camarero J, et al. The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur J Cancer 2012; 48:237-242.
11. Sanford M. Ipilimumab: in previously treated patients with advanced melanoma. BioDrugs 2012; 26:185-193.
12. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.
13. Bristol-Myers Squibb Pharma EEIG. Yervoy 5 mg/ml concentrate for solution for infusion: summary of product characteristics 2012; London: Bristol-Myers Squibb Pharma EEIG. Available at: http://www.emea.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/002213/WC500109299.pdf. [Accessed 28 May 2013].
14. Bristol-Myers Squibb Company. Yervoy (ipilimumab) prescribing information 2013; New York: Bristol-Myers Squibb Company. Available at: http://packageinserts.bms.com/pi/pi-yervoy.pdf. [Accessed 28 May 2013].
15. Arance A, Blanco R, LópezCriado P, Leon L, Rodriguez Abreu D, Espinosa E, et al. Experience of the Spanish Melanoma Group with the ipilimumab Expanded Access Program. Annual Meeting of the Spanish Society of Medical Oncology (SEOM). Madrid, Spain; 2012.
16. Berrocal A, Lopez-Martin JA, Arance AM, Soriano V, Espinosa E, Pilar Lopez Criado M, et al. Spanish experience with the ipilimumab Expanded Access Program [abstract]. J Clin Oncol 2012; 30:e19023.
17. Di Giacomo AM, Calabrò L, Danielli R, Pesce I, Fonsatti E, Bertocci E, et al. Long term survival and immunological correlates in metastatic melanoma treated with ipilimumab at 10 mgs within an Expanded Access Program [abstract 1117PD]. Ann Oncol 2012; 23: ix361-ix375.
18. Lopez Martin JA, Cao MG, Sereno M, Mayordomo J, Hidalgo M, Campos B, et al. Ipilimumab in older patients: Spanish melanoma multidisciplinary group (GEM) experience in the Expanded Access Programme (EAP) [abstract 1151]. Ann Oncol 2012; 23:ix361-ix375.
19. Martin Algarra S, Alonso L, Valdivia J, Garcia Castaño A, Escrig V, Mut P, et al. Spanish melanoma multidisciplinary group (GEM) experience with ipilimumab (IPI) in the Expanded Access Programme (EAP) [abstract 1150]. Ann Oncol 2012; 23:ix361-ix375.
20. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11:155-164.
21. Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One 2013; 8:e53745.
22. Di Giacomo AM, Danielli R, Calabrò L, Bertocci E, Nannicini C, Giannarelli D, et al. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunol Immunother 2011; 60:467-477.
23. Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 2010; 116:1767-1775.
24. Schmidt H, Suciu S, Punt CJ, Gore M, Kruit W, Patel P, et al. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. J Clin Oncol 2007; 25:1562-1569.
25. Konstantinou MP, Dutriaux C, Gaudy-Marqueste C, Mortier L, Bedane C, Girard C, et al. Ipilimumab in melanoma patients with brain metastasis: a retro-spective multicentre evaluation of thirty-eight patients. Acta Derm Venereol 2014; 94:45-49.
26. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516.
27. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366:707-714.
28. Ascierto PA, Simeone E, Giannarelli D, Grimaldi AM, Romano A, Mozzillo N. Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J Transl Med 2012; 10:107.